Cargando…
Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET
PURPOSE: Almost all radiolabellings of antibodies with (89)Zr currently employ the hexadentate chelator desferrioxamine (DFO). However, DFO can lead to unwanted uptake of (89)Zr in bones due to instability of the resulting metal complex. DFO*-NCS and the squaramide ester of DFO, DFOSq, are novel ana...
Autores principales: | Chomet, Marion, Schreurs, Maxime, Bolijn, Maria J., Verlaan, Mariska, Beaino, Wissam, Brown, Kari, Poot, Alex J., Windhorst, Albert D., Gill, Herman, Marik, Jan, Williams, Simon, Cowell, Joseph, Gasser, Gilles, Mindt, Thomas L., van Dongen, Guus A. M. S, Vugts, Danielle J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036225/ https://www.ncbi.nlm.nih.gov/pubmed/32889615 http://dx.doi.org/10.1007/s00259-020-05002-7 |
Ejemplares similares
-
Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for (89)Zr-immuno-PET
por: Vugts, Danielle J., et al.
Publicado: (2016) -
Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6
Chimeric mAb U36 and [(89)Zr]Zr-DFO-PEG(5)-Tz
por: Lumen, Dave, et al.
Publicado: (2022) -
Application of (89)Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody
por: Stergiou, N., et al.
Publicado: (2023) -
Performance of nanoScan PET/CT and PET/MR for quantitative imaging of (18)F and (89)Zr as compared with ex vivo biodistribution in tumor-bearing mice
por: Chomet, Marion, et al.
Publicado: (2021) -
Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for (89)Zr-immunoPET
por: Raavé, René, et al.
Publicado: (2019)